InMed appoints Nicole Lemerond to board; Adam Cutler resigns

InMed Pharmaceuticals Inc.

Adam Cutler resigned from board effective Aug 8, 2022; no disagreement with the company.
Nicole Lemerond appointed to board effective Aug 8, 2022; fills vacancy on Audit and Governance Committees.
Ms. Lemerond has 25+ years in investment management, private equity, healthcare finance; CFA charterholder.
Standard director compensation: $45,000 annual retainer plus options for 14,000 common shares.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nicole Lemerond

Director

INM · InMed Pharmaceuticals Inc.

Effective: 2022-08-08
Filed: August 11, 2022, 7:59 PM ET

the Board appointed Nicole Lemerond as a director of the Board to fill the vacancy created by Mr. Cutler’s resignation, effective as of August 8, 2022.

Departed

Adam Cutler

Director

INM · InMed Pharmaceuticals Inc.

Effective: 2022-08-08
Successor: Nicole Lemerond
Filed: August 11, 2022, 7:59 PM ET

Adam Cutler resigned from the Board of Directors (the “Board”) (including from the Nominating & Corporate Governance Committee and the Audit Committee) of the Company, effective as of August 8, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicole Lemerond was appointed as Director at InMed Pharmaceuticals Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Nicole Lemerond as a director of the Board to fill the vacancy created by Mr. Cutler’s resignation, effective as of August 8, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam Cutler resigned as Director at InMed Pharmaceuticals Inc..

Action: resigned
Role: Director

Exact text from the filing

Adam Cutler resigned from the Board of Directors (the “Board”) (including from the Nominating & Corporate Governance Committee and the Audit Committee) of the Company, effective as of August 8, 2022.

View on SEC.gov

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-046528

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.